EFFICIENCY OF THE NEW MEDICATION OF FS-1 IN THE TREATMENT OF EXPERIMENTAL TUBERCULOSIS
Abstract
In vitro studies have proved the anti-tuberculosis eect of FS-1 medication both against susceptible strain of M. tuberculosis H37Rv, and the strain of M. tuberculosis MS-115 with multiple drug resistance.
Conducted in vivo studies on guinea pigs infected with the pathogenic culture of human tuberculosis (strain of H37Rv), have shown that FS-1 provides expressed anti-inflammatory action on the course of experimental tuberculosis.
About the Authors
M. E. Kulmanov
Research Center of Anti-Infectious Medications
Kazakhstan
Kazakhstan
B. F. Kerimzhanova
Research Center of Anti-Infectious Medications
Kazakhstan
Almaty
Kazakhstan
Almaty
L. N. Chernousova
Central Tuberculosis Research Institute, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
I. V. Bocharova
Central Tuberculosis Research Institute, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
L. N. Lepekha
Central Tuberculosis Research Institute, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
A. I. Il'in
Research Center of Anti-Infectious Medications
Kazakhstan
Almaty
Kazakhstan
Almaty
References
1. Korovkin V.S. Molecular basics of drug resistance in tuberculous mycobacteria. Med. Novosti. 2003, no. 9, pp. 8-13. (In Russ.)
2. Prozorov А.А., Fedorova I.А., Bekker O.B. et al. Virulence factors of Mycobacterium tuberculosis: genetic monitoring, new concepts. Genetika, 2014, vol. 50, no. 8, pp. 885-908. (In Russ.)
3. World Health Organization. Global tuberculosis report 2013, World Health Organization. 2013, 289 p.
Review
For citations:
Kulmanov M.E., Kerimzhanova B.F., Chernousova L.N., Bocharova I.V., Lepekha L.N., Il'in A.I. EFFICIENCY OF THE NEW MEDICATION OF FS-1 IN THE TREATMENT OF EXPERIMENTAL TUBERCULOSIS. Tuberculosis and Lung Diseases. 2015;(12):50-56. (In Russ.)
Views:
739
Email this article 